Improvement of transmucosal absorption of drugs in drug delivery system (DDS) 4. Improvement of transmucosal absorption of protein and peptide drugs by cyclodextrins

Drug Delivery System

Volumn 20, Issue 4, 2005, Pages 433-442

  Arima, Hidetoshi ^a   Uekama, Kaneto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

absorption; eydodextrin; peptide; protein; transnincosal

Indexed keywords

EID: 85010140241     PISSN: 09135006     EISSN: 18812732     Source Type: Journal    
DOI: 10.2745/dds.20.433     Document Type: Article

References (57)

1. Uekama K, Hirayama F, Irie T: Cyclodextrin drug carrier systems. Chem Rev 98: 2045-2076, 1998.
2. Irie T, Uekama K: Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev 36: 101-123, 1999.
3. Uekama K, Kondo T, Nakamura K, Irie T, Arakawa K et al.: Modification of rectal absorption of morphine from hollow-type suppositories with a combination of α-cyclodextrin and viscosity-enhancing polysaccharide. J Pharm Sci 84: 15-20, 1995.
4. Kondo T, Irie T, Uekama K: Combination effects of α-cyclodextrin and xanthan gum on rectal absorption and metabolism of morphine from hollow-type suppositories in rabbits. Biol Pharm Bull 19: 280-286, 1996.
5. Watanabe Y, Matsumoto Y, Seki M, Takase M, Matsumoto M: Absorption enhancement of polypeptide drugs by cyclodextrins. I. Enhanced rectal absorption of insulin from hollow-type suppositories containing insulin and cyclodextrins in rabbits. Chem Pharm Bull 40: 3042-3047, 1992.
6. Watanabe Y, Kiriyama M, Ito R, Kikuchi R, Mizufune Y et al: Pharmacodynamics and pharmacokinetics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) after administration of a rectal dosage vehicle. Biol Pharm Bull 19: 1059-1063, 1996.
7. Kowari K, Hirosawa I, Kurai H, Utoguchi N, Fujii M et al.: Pharmacokinetics and pharmacodynamics of human chorionic gonadotropin (hCG) after rectal administration of hollow-type suppositories containing hCG. Biol Pharm Bull 25: 678-681, 2002.
8. Schipper NG, Verhoef JC, de Lannoy LM, Romeijn SG, Brakkee JH et al.: Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-β-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics. Br J Pharmacol 110: 1335-1340, 1993.
9. Igawa T, Maitani Y, Machida Y, Nagai T: Enzyme immunoassay of human fibroblast interferon after intranasal administration with several excipients in rabbits. Chem Pharm Bull 36: 3055-3059, 1988.
10. Matsubara K, Ando Y, Irie T, Uekama K: Protection afforded by maltosyl-β-cyclodextrin against α-chymotrypsin-catalyzed hydrolysis of a luteinizing hormone-releasing hormone agonist, buserelin acetate. Pharm Res 14: 1401-1405, 1997.
11. Irwin WJ, Dwivedi AK, Holbrook PA. Dey MJ: The effect of cyclodextrins on the stability of peptides in nasal enzymic systems. Pharm Res 11: 1698-1703, 1994.
12. Chun IK, Chien YW: Stabilization of methionine enkephalin in various rabbit mucosal extracts by enzyme inhibitors. Int J Pharm 121: 217-231, 1995.
13. Merkus FW, Verhoef JC, Romeijn SG, Schipper NG: Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm Res 8: 588-592, 1991.
14. Shao Z, Krishnamoorthy R, Mitra AK: Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations. Pharm Res 9: 1157-1163, 1992.
15. Irie T, Wakamatsu K, Arima H, Aritomi H, Uekama K: Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int J Pharm 84: 129-139, 1992.
16. Watanabe Y, Matsumoto Y, Kawamoto K, Yazawa S, Matsumoto M: Enhancing effect of cyclodextrins on nasal absorption of insulin and its duration in rabbits. Chem Pharm Bull 40: 3100-3104, 1992.
17. Watanabe Y, Matsumoto Y, Yamaguchi M, Kikuchi R, Takayama K et al: Absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and blood leukocyte dynamics following intranasal administration in rabbits. Biol Pharm Bull 16: 93-95. 1993.
18. Watanabe Y, Matsumoto Y, Kikuchi R, Kiriyama M, Nakagawa K et al.: Pharmacokinetics and pharmacodynamics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) following intranasal administration in rabbits. J Drug Target 3: 231-238, 1995.
19. Yetkin G, Celebi N, Agabeyoglu I, Gokcora N: The effect of dimethy-β-cyclodextrin and sodium taurocholate on the nasal bioavailability of salmon calcitonin in rabbits. STP Pharma Sci 9: 249-252, 1999.
20. Yetkin G, Celebi N, Agabeyoglu I, Gokcora N: Enhancement of nasal absorption of salmon calcitonin in rabbits using absorption enhancer. STP Pharma Sci 11: 187-191, 2001.
21. Sinswat P, Tengamnuay P: Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-β-cyclodextrins. Int J Pharm 257: 15-22, 2003.
22. Matsubara K, Abe K, Irie T, Uekama K: Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. J Pharm Sci 84: 1295-1300, 1995.
23. Adjei A, Sundberg D, Miller J, Chun A: Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res 9: 244-249, 1992.
24. Shimamoto T: Pharmaceutical aspects. Nasal and depot formulations of leuprolide. J Androl 8: S14-16, 1987.
25. Marttin E, Verhoef JC, Romeijn SG, Zwart P, Merkus FW: Acute hitopathological effects of benzalconium chloride and absorption enhancers in rat nasal epithelium in vivo. Int J Pharm 141: 151-160, 1996.
26. Marttin E, Verhoef JC, Romeijn SG, Merkus FW: Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm Res 12: 1151-1157, 1995.
27. Romeijin SG, Verhoef JC, Marttin E, Merkus FW: The effect of nasal drug formulations on ciliary beating in vivo. Int J Pharm 135: 137-145, 1996.
28. Abe K, Irie T, Uekama K: Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-β-cyclodextrin. Chem Pharm Bull 43: 2232-2237, 1995.
29. Abe K, Irie T, Adachi H, Uekama K: Combined use of 2-hydroxypropyl-β-cyclodextrin and a lipophilic absorption enhancer in nasal delivery of the LHRH agonist, buserelin acetate, in rats. Int J Pharm 123: 103-112, 1995.
30. Irie T, Abe K, Adachi H, Uekama K, Manako T et al.: Potential use of 2-hydroxypropyl-β-cyclodextrin in designing nasal preparation of insulin involving lipophilic absorption enhancer HPE-101. Drug Delivery System 7: 91-95. 1992.
31. Agerholm C, Bastholm L, Johansen PB, Nielsen MH, Elling F: Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers didecanoyl-L-α-phosphatidylcholine and α-cyclodextrin in rabbits. J Pharm Sci 83: 1706-1711, 1994.
32. Zhang Y, Jiang XG, Yao J: Nasal absorption enhancement of insulin by sodium deoxycholate in combination with cyclodextrins. Acta Pharmacol Sci 22: 1051-1056, 2001.
33. Yu S, Zhao Y, Wu F, Zhang X, Lu W et al.: Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int J Pharm 281: 11-23, 2004.
34. Merkus FWHM, Verhoef JC, Romeijn SG, Schipper NG: Interspecies differences in the nasal absorption of insulin. Pharm Res 8: 1343, 1991.
35. Merkus FWHM, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PH et al.: Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 36: 41-57, 1999.
36. Loftsson T, Jarho P, Masson M, Jarvinen T: Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2: 335-351, 2005.
37. Shao ZZ, Li YP, Mitra AK: Cyclodextrins as mucosal absorption of insulin. Part 3 Pulmonary route delivery. Eur J Pharm Biopharm 40: 283-288, 1994.
38. Kobayashi S, Kondo S, Juni K: Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res 13: 80-83, 1996.
39. Shao ZJ, Mitra AK: Pulmonary absorption of recombinant human growth hormone in rats. Eur J Pharm Biopharm 42: 199-203. 1996.
40. Hussain A, Yang T, Zaghloul AA, Ahsan F: Pulmonary absorption of insulin mediated by tetradecyl-β-maltoside and dimethyl-β-cyclodextrin. Pharm Res 20: 1551-1557, 2003.
41. Nakate T, Yoshida H, Ohike A, Tokunaga Y, Ibuki R et al.: Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with β-cyclodextrin. Eur J Pharm Biopharm 55: 147-154, 2003.
42. Nakate T, Yoshida H, Ohike A, Tokunaga Y, Ibuki R et al.: Comparison of the lung absorption of FK224 inhaled from a pressurized metered dose inhaler and a dry powder inhaler by healthy volunteers. Eur J Pharm Biopharm 56: 319-325, 2003.
43. Aguiar MM, Rodrigues JM, Silva Cunha A: Encapsulation of insulin-cyclodextrin complex in PLGA microspheres: a new approach for prolonged pulmonary insulin delivery. J Microencapsul 21: 553-564, 2004.
44. Koushik K, Dhanda DS, Cheruvu NP, Kompella UB: Pulmonary delivery of deslorelin: large-porous PLGA particles and HP-β-CD complexes. Pharm Res 21: 1119-1126, 2004.
45. Kumar TM, Misra A: Pulmonary absorption enhancement of salmon calcitonin. J Drug Target 12: 135-144, 2004.
46. Nimbalkar D, Birudaraj R, Jones PR, Smith TJ: Activation of diacetyldapsone and a preliminary evaluation of a cyclodextrin-diacetyldapsone complex in cultured lung cells. Biotechnol Appl Biochem 33: 123-125, 2001.
47. Evrard B, Bertholet P, Gueders M, Flament MP, Piel G et al.: Cyclodextrins as a potential carrier in drug nebulization. J Control Release 96: 403-410, 2004.
48. Kanai A, Alba RM, Takano T, Kobayashi C, Nakajima A et al.: The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. Transplant Proc 21: 3150-3152, 1989.
49. Takano T, Kobayashi C, Alba RM, Kanai A: The immunosuppressive effects of 0.025% cyclosporin eye drops in α-cyclodextrin on rabbit corneal allografts. Nippon Ganka Gakkai Zasshi 96: 834-840, 1992.
50. Mills RA, Jones DB, Winkler CR, Wallace GW, Wilhelmus KR: Topical FK-506 prevents experimental corneal allograft rejection. Cornea 14: 157-160, 1995.
51. Kim EY, Gao ZG, Park J-S, Li H, Han K: EGF-HP-β-CD complex in poloxamer gel for ophthalmic delivery. Int J Pharm 233: 159-167, 2002.
52. Arima H, Yunomae K, Hirayama F, Uekama K: Contribution of P-glycoprotein to the enhancing effects of dimethyl-β-cyclodextrin on oral bioavailability of tacrolimus. J Pharmacol Exp Tiler 297: 547-555, 2001.
53. Arima H, Yunomae K, Morikawa T, Hirayama F, Uekama K: Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-β-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm Res 21: 625-634, 2004.
54. Radwan MA, Aboul-Enein HY: The effect of absorption enhancers on the initial degradation kinetics of insulin by α-chmotrypsin. Int J Pharm 217: 111-120, 2001.
55. Ahsan F, Arnold JJ, Yang T, Meezan E, Schwiebert EM et al.: Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-β-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-). Eur J Pharm Sci 20: 27-34, 2003.
56. Marttin E, Verhoef JC, Merkus FW: Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target 6: 17-36, 1998.
57. Cabral Marques HM, Hadgraft J, Kellaway IW, Taylor G: Studies of cyclodextrin inclusion complexes III. The pulmonary absorption of β-, DM-β- and HP-β-cyclodextrins in rabbits. Int J Pharm 77: 297-302, 1991.